JP2021534829A5 - - Google Patents

Info

Publication number
JP2021534829A5
JP2021534829A5 JP2021535497A JP2021535497A JP2021534829A5 JP 2021534829 A5 JP2021534829 A5 JP 2021534829A5 JP 2021535497 A JP2021535497 A JP 2021535497A JP 2021535497 A JP2021535497 A JP 2021535497A JP 2021534829 A5 JP2021534829 A5 JP 2021534829A5
Authority
JP
Japan
Prior art keywords
receptor
soluble
chain chimeric
target
binding domain
Prior art date
Application number
JP2021535497A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534829A (ja
JPWO2020047333A5 (https=
JP7407822B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048930 external-priority patent/WO2020047333A1/en
Publication of JP2021534829A publication Critical patent/JP2021534829A/ja
Publication of JPWO2020047333A5 publication Critical patent/JPWO2020047333A5/ja
Publication of JP2021534829A5 publication Critical patent/JP2021534829A5/ja
Priority to JP2023214081A priority Critical patent/JP7750929B2/ja
Application granted granted Critical
Publication of JP7407822B2 publication Critical patent/JP7407822B2/ja
Priority to JP2025158968A priority patent/JP2026001088A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021535497A 2018-08-30 2019-08-29 単鎖キメラポリペプチドおよびその使用 Active JP7407822B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023214081A JP7750929B2 (ja) 2018-08-30 2023-12-19 単鎖キメラポリペプチドおよびその使用
JP2025158968A JP2026001088A (ja) 2018-08-30 2025-09-25 単鎖キメラポリペプチドおよびその使用

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201862725038P 2018-08-30 2018-08-30
US62/725,038 2018-08-30
US201862746832P 2018-10-17 2018-10-17
US62/746,832 2018-10-17
US201862749506P 2018-10-23 2018-10-23
US62/749,506 2018-10-23
US201962816683P 2019-03-11 2019-03-11
US62/816,683 2019-03-11
US201962817241P 2019-03-12 2019-03-12
US201962817244P 2019-03-12 2019-03-12
US62/817,241 2019-03-12
US62/817,244 2019-03-12
US201962881039P 2019-07-31 2019-07-31
US62/881,039 2019-07-31
PCT/US2019/048930 WO2020047333A1 (en) 2018-08-30 2019-08-29 Single-chain chimeric polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023214081A Division JP7750929B2 (ja) 2018-08-30 2023-12-19 単鎖キメラポリペプチドおよびその使用

Publications (4)

Publication Number Publication Date
JP2021534829A JP2021534829A (ja) 2021-12-16
JPWO2020047333A5 JPWO2020047333A5 (https=) 2022-08-05
JP2021534829A5 true JP2021534829A5 (https=) 2022-08-05
JP7407822B2 JP7407822B2 (ja) 2024-01-04

Family

ID=67953880

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021535497A Active JP7407822B2 (ja) 2018-08-30 2019-08-29 単鎖キメラポリペプチドおよびその使用
JP2023214081A Active JP7750929B2 (ja) 2018-08-30 2023-12-19 単鎖キメラポリペプチドおよびその使用
JP2025158968A Pending JP2026001088A (ja) 2018-08-30 2025-09-25 単鎖キメラポリペプチドおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023214081A Active JP7750929B2 (ja) 2018-08-30 2023-12-19 単鎖キメラポリペプチドおよびその使用
JP2025158968A Pending JP2026001088A (ja) 2018-08-30 2025-09-25 単鎖キメラポリペプチドおよびその使用

Country Status (11)

Country Link
US (4) US11401324B2 (https=)
EP (1) EP3843788A1 (https=)
JP (3) JP7407822B2 (https=)
KR (1) KR20210069639A (https=)
CN (2) CN120535649A (https=)
AU (2) AU2019328313B2 (https=)
CA (1) CA3108951A1 (https=)
IL (2) IL280915B2 (https=)
SG (1) SG11202101780WA (https=)
TW (2) TW202530272A (https=)
WO (1) WO2020047333A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111315395A (zh) 2017-09-06 2020-06-19 耶鲁大学 白细胞介素-18变体和使用方法
US11518792B2 (en) 2018-08-30 2022-12-06 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
US11401324B2 (en) 2018-08-30 2022-08-02 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CA3109361A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Il13を含む融合タンパク質
CN120924491A (zh) 2019-06-21 2025-11-11 免疫生物公司 多链嵌合多肽和其用途
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
AU2021220870A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
WO2021163299A1 (en) * 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
EP4121087A4 (en) 2020-03-18 2024-04-03 The University of Hong Kong ANTI-VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE
WO2021202354A1 (en) * 2020-03-30 2021-10-07 Proviva Therapeutics (Hong Kong) Limited Il-2/il-15 compositions and methods of use thereof
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
JP2023527869A (ja) * 2020-06-01 2023-06-30 エイチシーダブリュー バイオロジックス インコーポレイテッド 加齢関連障害の治療法
WO2021247003A1 (en) * 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
US20240148820A1 (en) * 2021-02-17 2024-05-09 Versitech Limited Anti-viral peptides and compositions and methods of use thereof
WO2023201311A1 (en) 2022-04-13 2023-10-19 HCW Biologics, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
CN116059348A (zh) * 2022-09-16 2023-05-05 四川大学华西医院 基于nkg2d的细胞接合器分子在清除衰老细胞中的应用
WO2025096644A1 (en) * 2023-10-31 2025-05-08 Immunitybio, Inc. Multi-chain chimeric polypeptides and use thereof in the treatment of advanced solid tumors

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2521593B2 (ja) 1991-06-07 1996-08-07 和久 白山 コンクリ―ト供試体の加圧方法とアタッチメント
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
AU702250B2 (en) * 1994-07-11 1999-02-18 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6117980A (en) 1997-02-21 2000-09-12 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc TGF−βII型受容体に対するヒトモノクローナル抗体及びその医薬用途
AU2270101A (en) * 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
ATE333900T1 (de) * 2000-02-24 2006-08-15 Philogen Spa Zusamensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
PT1355919E (pt) * 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
ES2353273T3 (es) 2000-12-26 2011-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos anti-cd28.
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US7371371B2 (en) 2001-08-13 2008-05-13 University Of Southern California Interleukin-2 mutants with reduced toxicity
TWI338009B (en) 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
WO2003104425A2 (en) 2002-06-07 2003-12-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Novel stable anti-cd22 antibodies
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2357009A1 (en) 2002-07-15 2011-08-17 Board of Regents, The University of Texas System Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections
JP4463104B2 (ja) 2002-08-30 2010-05-12 財団法人化学及血清療法研究所 ヒト抗ヒトインターロイキン−6抗体及び該抗体フラグメント
EP1400534B1 (en) 2002-09-10 2015-10-28 Affimed GmbH Human CD3-specific antibody with immunosuppressive properties
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
WO2004076488A1 (en) 2003-02-27 2004-09-10 Theravision Gmbh A molecule which binds cd80 and cd86
KR20060015482A (ko) 2003-03-21 2006-02-17 와이어쓰 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료
JP4638876B2 (ja) 2003-05-23 2011-02-23 ワイス Gitrリガンド及びgitrリガンド関連分子及び抗体及びその使用
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
JP2005124568A (ja) 2003-10-01 2005-05-19 Junichi Masuyama 細胞活性化方法及びこれを用いる細胞製造方法並びに医薬組成物
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
ES2375481T3 (es) 2004-03-30 2012-03-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticuerpos biespecíficos para elegir como diana células que participan en reacciones de tipo alérgico, composiciones y usos de los mismos.
WO2006086469A2 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
US7393833B2 (en) 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
AU2006224313B2 (en) 2005-03-17 2011-08-11 Ucl Biomedica Plc Method for actvating Natural Killer cells by tumor cell preparation in vitro
CN100509849C (zh) 2005-04-07 2009-07-08 苏州大学 可溶性人cd28分子检测试剂盒及其应用
CN101203241B (zh) 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
CA2763671A1 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
ATE459648T1 (de) 2005-05-11 2010-03-15 Philogen Spa Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2009120922A2 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
LT3216803T (lt) 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US9273136B2 (en) 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
WO2011127324A2 (en) 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗tim-3抗体
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP2012034668A (ja) 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗egfr抗体リジン置換可変領域断片及びその利用
CN107880136B (zh) 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
WO2012051147A1 (en) 2010-10-11 2012-04-19 Abbott Laboratories Processes for purification of proteins
CN102153653B (zh) 2010-12-30 2012-08-15 厦门大学 肿瘤血管靶向多肽与组织因子的融合蛋白及其制备方法
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
CN105884900A (zh) 2011-04-19 2016-08-24 梅里麦克制药股份有限公司 单特异性和双特异性抗igf-1r和抗erbb3抗体
SMT201800269T1 (it) 2011-04-25 2018-07-17 Daiichi Sankyo Co Ltd Anticorpo anti-b7-h3
SG10201603962TA (en) 2011-05-25 2016-07-28 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory disorders
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
SG195253A1 (en) 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
WO2012170470A1 (en) 2011-06-06 2012-12-13 Board Of Regents Of The University Of Nebraska Compositions and methods for detection and treatment of cancer
CN103747803B (zh) 2011-06-22 2016-10-12 国家医疗保健研究所 抗axl抗体及其用途
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
AU2012335205A1 (en) 2011-11-11 2014-05-29 Rinat Neuroscience Corp. Antibodies specific for Trop-2 and their uses
EP4372084A3 (en) * 2012-01-26 2024-08-14 Tecan Genomics, Inc. Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation
US10259626B2 (en) 2012-03-08 2019-04-16 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
KR101535341B1 (ko) 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
CA2876285A1 (en) 2012-08-08 2014-02-13 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
US20150218280A1 (en) 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2014033130A1 (en) 2012-08-28 2014-03-06 Institut Curie Cluster of differentiation 36 (cd36) as a therapeutic target for hiv infection
HUE033369T2 (en) 2012-11-20 2017-11-28 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
WO2014095808A1 (en) 2012-12-17 2014-06-26 Delenex Therapeutics Ag Antibodies against il-1 beta
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
TW201446794A (zh) 2013-02-20 2014-12-16 Novartis Ag 利用抗-cd123嵌合抗原受體工程化t細胞之初級人類白血病有效靶向
WO2014159531A1 (en) 2013-03-14 2014-10-02 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting epcam for detection of prostate cancer lymph node metastases
AU2014268364A1 (en) 2013-05-24 2015-12-10 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
JP2015030666A (ja) 2013-07-31 2015-02-16 学校法人順天堂 抗ヒトcd26モノクローナル抗体又はその抗原結合性断片
CN103709251B (zh) 2013-12-19 2016-04-13 江苏众红生物工程创药研究院有限公司 全人源抗cd26抗体及其应用
KR102127408B1 (ko) 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
CA2937034A1 (en) * 2014-02-03 2015-08-06 Riken Anti-tissue factor monoclonal antibody
FR3021970B1 (fr) 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
AU2015305754B2 (en) 2014-08-19 2018-10-25 Merck Sharp & Dohme Llc Anti-tigit antibodies
MY193723A (en) 2014-08-29 2022-10-27 Hoffmann La Roche Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
JP7211703B2 (ja) 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗mertkアゴニスト抗体及びその使用
US10744157B2 (en) 2015-03-26 2020-08-18 The Trustees Of Dartmouth College Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
KR20170138494A (ko) 2015-04-17 2017-12-15 엘살리스 비오떼끄 항-tyr03 항체 및 이의 용도
KR101778439B1 (ko) 2015-04-27 2017-09-14 울산대학교 산학협력단 자연살해세포 활성화제를 유효성분으로 함유하는 면역증강 및 항암활성증진용 조성물
US10723793B2 (en) 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
KR20180061226A (ko) 2015-09-11 2018-06-07 와이즈에이씨가부시키가이샤 항cd26 항체와 다른 항암제를 조합한 암 치료용 조성물
CA2994858C (en) 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use
CN108367071B (zh) 2015-11-13 2022-05-13 达纳-法伯癌症研究所有限公司 用于癌症免疫疗法的nkg2d-ig融合蛋白
JP2019511911A (ja) 2016-02-17 2019-05-09 ノバルティス アーゲー Tgfベータ2抗体
MX2018010445A (es) 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
WO2017189526A1 (en) 2016-04-25 2017-11-02 Musc Foundation For Research Development Activated cd26-high immune cells and cd26-negative immune cells and uses thereof
ES3014658T3 (en) 2016-10-05 2025-04-23 Univ Central Florida Res Found Inc Methods and compositions related to nk cell and anti-pdl1 cancer therapies
CN118562016A (zh) * 2016-10-21 2024-08-30 艾尔特生物科技公司 基于多聚体il-15的分子
MX2019007981A (es) 2017-01-03 2019-10-15 Bioatla Llc Terapeutica de proteinas para el tratamiento de celulas senescentes.
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
CN110461357A (zh) 2017-02-28 2019-11-15 阿菲姆德股份有限公司 抗cd16a抗体与细胞因子的组合
CN117986384A (zh) 2017-03-06 2024-05-07 艾尔特生物科技公司 与il-12和il-18的基于il-15的融合物
EP3601538A4 (en) 2017-03-27 2021-03-10 Nantcell, Inc. ANK AND IL-12 COMPOSITIONS AND METHODS
EP3421607A1 (en) 2017-06-29 2019-01-02 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Identification and elimination of damaged and/or senescent cells
EP3676289B1 (en) 2017-08-28 2026-03-04 Altor BioScience, LLC Il-15-based fusions to il-7 and il-21
US11401324B2 (en) 2018-08-30 2022-08-02 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CA3109361A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
US11518792B2 (en) 2018-08-30 2022-12-06 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CN120924491A (zh) 2019-06-21 2025-11-11 免疫生物公司 多链嵌合多肽和其用途
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
AU2021220870A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
CA3169243A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
WO2023201311A1 (en) 2022-04-13 2023-10-19 HCW Biologics, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder

Similar Documents

Publication Publication Date Title
JP2021534829A5 (https=)
JP2021534828A5 (https=)
JP2021534835A5 (https=)
JPWO2020047299A5 (https=)
JPWO2020047473A5 (https=)
JPWO2020047333A5 (https=)
US20230295567A1 (en) Methods for culturing cells and kits and apparatus for same
JP2021535225A5 (https=)
CN112469829B (zh) 包含抗gpc3单链抗体的car
CN109069537B (zh) 共刺激结构域中具有重复结合基序的car
CN112105633A (zh) 新型白介素2及其用途
TW202016295A (zh) Car表現t細胞及car表現載體
EP3615653A1 (en) Oligomeric particle reagents and methods of use thereof
CN111417652A (zh) 嵌合多肽及其用途
JP2019513347A5 (https=)
CN110121505A (zh) 嵌合抗原受体和表达其的自然杀伤细胞
CA3079076A1 (en) Methods and compounds for improved immune cell therapy
EP3768700A1 (en) Chimeric transmembrane proteins and uses thereof
KR20190046854A (ko) Bcma-특이적 피브로넥틴 iii 형 도메인을 포함하는 키메라 항원 수용체 및 그의 용도
JP7746263B2 (ja) 細胞選択および/または細胞刺激デバイスならびに使用方法
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
CN110423757B (zh) 一种工程化核酸、t细胞及其应用和产生方法
CN112048481A (zh) 一种靶向cd19的嵌合抗原受体nk细胞及其应用
US20210309717A1 (en) Novel Recombinant Cell Surface Markers
CN112996819B (zh) 细胞分选系统及使用方法